Heron Therapeutics, Inc. (0J4V.L)
USD 1.62
(0.31%)
USD 1.62
(0.31%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 256.47 Million USD | 8.05% |
| 2022 | 237.37 Million USD | 4.05% |
| 2021 | 228.13 Million USD | 94.88% |
| 2020 | 117.06 Million USD | 7.45% |
| 2019 | 108.94 Million USD | 18.4% |
| 2018 | 92.01 Million USD | -10.81% |
| 2017 | 103.17 Million USD | 16.27% |
| 2016 | 88.73 Million USD | 349.62% |
| 2015 | 19.73 Million USD | 44.9% |
| 2014 | 13.62 Million USD | 94.79% |
| 2013 | 6.99 Million USD | 68.32% |
| 2012 | 4.15 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 251.65 Million USD | -1.88% |
| 2024 Q2 | 256.07 Million USD | 1.76% |
| 2023 Q2 | 240.5 Million USD | 3.53% |
| 2023 Q1 | 232.3 Million USD | -2.14% |
| 2023 Q3 | 256.98 Million USD | 6.85% |
| 2023 Q4 | 256.47 Million USD | -0.2% |
| 2023 FY | 256.47 Million USD | 8.05% |
| 2022 Q2 | 265.7 Million USD | 6.38% |
| 2022 Q1 | 249.76 Million USD | 9.48% |
| 2022 FY | 237.37 Million USD | 4.05% |
| 2022 Q4 | 237.37 Million USD | -4.86% |
| 2022 Q3 | 249.5 Million USD | -6.1% |
| 2021 Q4 | 228.13 Million USD | -2.32% |
| 2021 Q3 | 233.54 Million USD | -4.34% |
| 2021 FY | 228.13 Million USD | 94.88% |
| 2021 Q1 | 114.7 Million USD | -2.01% |
| 2021 Q2 | 244.13 Million USD | 112.84% |
| 2020 Q1 | 113.47 Million USD | 4.15% |
| 2020 FY | 117.06 Million USD | 7.45% |
| 2020 Q2 | 108.66 Million USD | -4.24% |
| 2020 Q3 | 112.87 Million USD | 3.88% |
| 2020 Q4 | 117.06 Million USD | 3.71% |
| 2019 Q4 | 108.94 Million USD | 1.33% |
| 2019 Q3 | 107.52 Million USD | 1.14% |
| 2019 Q2 | 106.3 Million USD | 2.24% |
| 2019 Q1 | 103.98 Million USD | 13.0% |
| 2019 FY | 108.94 Million USD | 18.4% |
| 2018 FY | 92.01 Million USD | -10.81% |
| 2018 Q4 | 92.01 Million USD | 43.58% |
| 2018 Q3 | 64.08 Million USD | -18.53% |
| 2018 Q2 | 78.66 Million USD | -13.72% |
| 2018 Q1 | 91.17 Million USD | -11.63% |
| 2017 Q3 | 78.14 Million USD | 6.61% |
| 2017 FY | 103.17 Million USD | 16.27% |
| 2017 Q2 | 73.29 Million USD | -16.14% |
| 2017 Q1 | 87.39 Million USD | -1.5% |
| 2017 Q4 | 103.17 Million USD | 32.03% |
| 2016 Q3 | 80.92 Million USD | 190.16% |
| 2016 Q2 | 27.89 Million USD | 45.49% |
| 2016 Q4 | 88.73 Million USD | 9.65% |
| 2016 FY | 88.73 Million USD | 349.62% |
| 2016 Q1 | 19.17 Million USD | -2.86% |
| 2015 FY | 19.73 Million USD | 44.9% |
| 2015 Q1 | 11.62 Million USD | -14.64% |
| 2015 Q4 | 19.73 Million USD | 19.97% |
| 2015 Q3 | 16.45 Million USD | -0.84% |
| 2015 Q2 | 16.59 Million USD | 42.7% |
| 2014 FY | 13.62 Million USD | 94.79% |
| 2014 Q2 | 10.79 Million USD | 46.15% |
| 2014 Q3 | 11.27 Million USD | 4.47% |
| 2014 Q4 | 13.62 Million USD | 20.81% |
| 2014 Q1 | 7.38 Million USD | 5.61% |
| 2013 Q3 | 5.49 Million USD | -42.68% |
| 2013 Q2 | 9.59 Million USD | 26.28% |
| 2013 Q4 | 6.99 Million USD | 27.17% |
| 2013 Q1 | 7.59 Million USD | 82.86% |
| 2013 FY | 6.99 Million USD | 68.32% |
| 2012 Q4 | 4.15 Million USD | 0.0% |
| 2012 FY | 4.15 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | -70.922% |
| Dynavax Technologies Corporation | 375.02 Million USD | 31.61% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 47.385% |
| Perrigo Company plc | 6.04 Billion USD | 95.755% |
| Illumina, Inc. | 4.36 Billion USD | 94.126% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.506% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -31.032% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.628% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 98.753% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 96.391% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -587.759% |
| Waters Corporation | 3.47 Billion USD | 92.623% |
| Biogen Inc. | 12.04 Billion USD | 97.871% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -211.136% |
| Evolus, Inc. | 209.68 Million USD | -22.315% |
| Adicet Bio, Inc. | 37.12 Million USD | -590.946% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -273.012% |
| bluebird bio, Inc. | 424.62 Million USD | 39.599% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 61.186% |
| FibroGen, Inc. | 585.72 Million USD | 56.212% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 94.785% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -629.108% |
| Homology Medicines, Inc. | 118.53 Million USD | -116.378% |
| Geron Corporation | 146.12 Million USD | -75.518% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 93.668% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 58.479% |
| Myriad Genetics, Inc. | 312.9 Million USD | 18.032% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -1177.859% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -2.261% |
| Zoetis Inc. | 9.29 Billion USD | 97.241% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -421.553% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 92.684% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 86.43% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 95.02% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -429.423% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 90.148% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 3.119% |
| Verastem, Inc. | 71.18 Million USD | -260.299% |
| Nektar Therapeutics | 267.04 Million USD | 3.957% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 35.438% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -537.595% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 89.337% |
| OPKO Health, Inc. | 622.47 Million USD | 58.797% |
| Exelixis, Inc. | 678.44 Million USD | 62.196% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 74.84% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -123.39% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -1946.266% |
| uniQure N.V. | 624.01 Million USD | 58.899% |
| Imunon, Inc. | 8.53 Million USD | -2906.637% |
| Blueprint Medicines Corporation | 918.64 Million USD | 72.081% |
| Insmed Incorporated | 1.66 Billion USD | 84.566% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 84.451% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -103.395% |
| TG Therapeutics, Inc. | 169.08 Million USD | -51.686% |
| Incyte Corporation | 1.59 Billion USD | 83.892% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 78.367% |